Using remote ischemic preconditioning to prevent kidney injury in septic patients
Official title: Effect of Remote Ischemic Preconditioning in Septic Patients on Cell Cycle Arrest Biomarkers - the RIPC-ICU Randomized Clinical Trial
Run by Universität Münster · NCT05830669 · Data updated 2026-11-12
This study is testing if a special technique that temporarily restricts blood flow in the arm can help prevent kidney injury in critically ill patients with sepsis.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 64 (estimated) |
| Sponsor | Universität Münster Academic / other |
| Locations | 1 site (Münster) |
| Status | Recruiting |
| Started | May 11, 2023 |
| Main results expected | October 2025 |
| Study ends | January 2026 |
| Registry record updated | December 12, 2024 |
| Trial ID | NCT05830669 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adult patients aged 18 and older who are critically ill with sepsis and require invasive ventilation or vasopressor therapy.
✕Probably not a fit
Patients with pre-existing acute kidney injury, chronic kidney disease, or those on chronic dialysis are unlikely to benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the use of remote ischemic preconditioning (RIPC) to reduce the incidence of acute kidney injury (AKI) in critically ill patients suffering from sepsis. The approach involves inducing ischemia in the upper limb through three cycles, which is hypothesized to provide protective effects on the kidneys. The effectiveness of RIPC will be assessed using urinary biomarkers such as tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7). The trial aims to establish a clinically viable method to mitigate AKI in this vulnerable patient population.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence and severity of acute kidney injury in critically ill septic patients.
How similar studies have gone: While the concept of remote ischemic preconditioning has been explored in various contexts, this specific application in septic patients with acute kidney injury is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (age ≥18 years) * Critically ill patients with sepsis \< 12 hours * Invasive ventilation for at least 24 hours (propofol-free-sedation) and/or vasopressor therapy * Unrestricted intensive care for at least 72 hours * Written informed consent Exclusion Criteria: * Pre-existing AKI * (Glomerulo-)nephritis, interstitial nephritis, vasculitis * Chronic kidney disease with estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73m² * Chronic dialysis dependency * Kidney transplant in the last 12 months * Oral antidiabetics, sulfonamides or nicorandil * Pregnancy or breastfeeding * Do-not-reanimate order * Participation in another interventional trial involving kidney outcomes within the last 3 months * Dependency on the investigator or center
Where it's running
-
University Hospital Münster; Department of Anesthesiology, Intensive Care Medicine and Pain Medicine
Münster, Germany Recruiting
Study contacts
- Principal investigator: Melanie Meersch-Dini, MD — University Hospital Muenster, Dept. of Anesthesiology, Intensive Care Therapy and Pain Medicine
- Study coordinator: Melanie Meersch-Dini, MD
- Email: meersch@uni-muenster.de
- Phone: +49-251-8347255
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Which antibiotic combo is safer for kidneys in serious hospital infections
This trial tests whether vancomycin with piperacillin/tazobactam is gentler on the kidneys than other common broad-spectrum antibiotics for adults with serious infections in the hospital.
-
Iron-chelator added to dialysis fluid in sepsis-related AKI on CRRT
In adults with sepsis-associated acute kidney injury requiring dialysis, this study tests whether adding the iron-binding drug MEX-CD1 to dialysis fluid helps remove more iron compared with standard dialysis fluid.
-
AZD4144 for sepsis-associated acute kidney injury
This will test whether IV AZD4144 given once daily can help adults with sepsis who recently developed acute kidney injury.
-
Testing SGLT2 inhibitors for treating sepsis in adults
This study is testing if a new type of diabetes medication can help adults with sepsis recover better and feel safer.
-
A large biobank for acute and emergency medicine
This study is collecting health information and samples from patients with sudden illnesses in the Emergency Department to see if it can help improve treatments and predict how patients will do.
-
Using blood purification therapy for critically ill patients
This study is trying to see which critically ill patients can benefit the most from a special blood purification treatment to help improve their recovery from serious conditions like kidney injury and sepsis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.